The authors mention in their results
that the final histopathology stage of colorectal cancer in both the open and laparoscopic surgery groups was similar, but the data were not shown. It has been well demonstrated in some studies that VEGF-C and -D (other members of the VEGF family) are overexpressed in approximately half of colorectal adenocarcinomas and are associated with the depth of tumor invasion, presence of lymphatic invasion, and lymph node metastasis. 2, 3 Therefore, these data are important and should be presented to the reader; although there may not be a statistically significant difference between groups, there may still be apparent disparity in numbers not detected by statistical analysis due to the relatively small numbers. 2. As the authors suggested, the changes in VEGF levels mirror the degree of surgical injury as shown by the correlation between length of surgical wound and VEGF levels. Therefore, it is likely that any differences in surgical procedure may influence the observed changes in VEGF concentrations. The authors stated that the type of colectomy performed was similar in patients undergoing open surgery and laparoscopic sur-gery in group A (colorectal cancer group). However, only 2 patients underwent laparoscopic low anterior resection as opposed to 9 in the open surgery group, which we have calculated to be a statistically significant difference (P ϭ 0.03 vs. authors' calculation of 0.05). There is still a significant difference when the analysis is performed with n ϭ 69 in the laparoscopic colorectal cancer group, which is the total that we obtained from the data in Table  1 . As low anterior resection requires extensive pelvic dissection to mobilize the rectum as compared with other colectomies (right or left), this in addition to the larger surgical wound may well could have further contributed to the elevated levels of VEGF in the immediate postoperative period in the open surgery group. Also, the total number of left-sided resections is greater in the open group, which may not be significantly different but could just represent a type II error. 3. Like VEGF, fibroblast growth factor-2 (FGF-2) is another potent angiogenic and growth factor that plays an important role in regulation of tumor growth and wound healing. 4 Its circulating levels have been shown to be increased following surgery 5, 6 as well as in patients with primary/metastatic colorectal cancer. 7 Recently, our group has presented the results of in vitro studies investigating the effect of FGF-2 on the SW620 metastatic colonic adenocarcinoma cell line treated with chemotherapeutic agents such as 5-fluorouracil and oxaliplatin. 8 Our results showed that FGF-2 offered significant protection to colonic cancer cells against the cytotoxic effects of both these chemotherapeutic agents by reducing apoptosis in the cancer cells as also observed in small cell lung cancer. 9 The authors, in their discussion, have suggested antiangiogenic therapy or conventional chemotherapy in the early postoperative period as options to prevent tumor development and metastasis in postresection cancer patients who are exposed to high levels of VEGF. In addition to problems of wound and anastomotic healing mentioned by the authors, there is a possibility that high levels of VEGF and other growth factors may similarly confer increased chemoresistance on the cancer cells in the immediate postoperative period. To avoid these problems, it may be worth considering antiangiogenic therapy or chemotherapy in the neoadjuvant setting. As can be seen, these groups were well matched in regard to stage. It should also be noted that there was no correlation between the stage of disease and postoperative plasma VEGF levels. 2. Prabhudesai et al commented that the extent of intraabdominal surgical trauma may be an important variable in regards to plasma VEGF levels after resection. They correctly point out that there was a difference in the number of low anterior resections (presumably more traumatic than colectomy) between the 2 groups (Lap, 2 patients; open, 9 patients). This might have had an impact on the overall results if there was a correlation between the extent of intraabdominal trauma and postoperative VEGF levels. In fact, no such relationship was found; when the low anterior resection (LAR) and the right colectomy group VEGF results were compared, there were no differences noted on either postoperative day 1 (P ϭ 0.93) or postoperative day 3 (P ϭ 0.89). Similarly, no differences were noted when the sigmoid, left colectomy, and right colectomy results were compared. A question was also raised regarding the LAR comparison P value (P ϭ 0.05). Although the "Methods" section stated that the Fisher exact test was used for the analysis, we used a 2 with Yates correction for the LAR comparison because of the small sample size in this subgroup. The 2 with Yates correction is the appropriate test in this instance because the minimum expected frequencies were 5.54 for the lap LAR and 5.46 for the open LAR group. The Fisher exact test (P ϭ 0.03 for LAR comparison) is the preferred method in this situation if the minimum expected frequency value is less than 5. 1 We apologize for this confusion.
Prabhudesai et al are questioning whether there are true differences in VEGF levels after open and closed surgery. Although there are differences during the first 3 days, when the first postoperative month is considered the open and closed surgery groups are probably far more similar than different in regards to plasma VEGF levels. In a recently completed study of minimally invasive cancer resection patients in whom multiple late blood samples were obtained, it was noted that median plasma VEGF levels continue to rise during the first week, peak during the third week, and remain significantly elevated for 4 weeks (publication pending). There are no late data for open colectomy patients yet; however, we anticipate similar results. We are less concerned with differences between open and closed methods than with surgery's impact, in general, on plasma VEGF levels. Unlike most of postoperative plasma compositional changes, which quickly resolve, it appears that plasma VEGF levels steadily rise and remain elevated for one month. Although unproven, this alteration may encourage the growth of residual micrometastases in patients with residual disease post resection. 3. In our manuscript, we encourage the development of early adjuvant therapy because host conditions after surgery favor tumor growth (increased plasma VEGF and MMP-9 levels, decreased IGFBP-3 levels, immunosuppression, etc). Prabhudesai et al believe that neoadjuvant therapy is more likely to be effective based on their in vitro FGF-2 tumor cell growth studies. FGF-2, blood levels of which are increased after surgery, was found to increase the resistance of the tumor cells to chemotherapeutic agents. We recognize that it will be difficult to find effective anticancer treatment of the early post surgery period; however, it is precisely because the tumor has the upper hand after surgery that we are proposing such treatment. Having said this, however, we agree that neoadjuvant treatment should be given during the immediate preoperative period. Thus, we propose the development of perioperative anticancer treatment regimens that would contain both preoperative and early postoperative elements.
Toward this end, we recently completed a small randomized trial that assessed the immunologic and angiogenic impact of perioperative granulocyte macrophage-colony-stimulating factor (GM-CSF) treatment (publication pending). GMCSF and other immunomodulators, experimentally, decrease tumor growth. 2,3 Our next clinical trial, similar to the FOXTROT study mentioned by Prabhudesai et al, will assess the impact of perioperative administration of a targeted receptor antibody. We think that the perioperative window holds great promise; it is hoped that other investigators will join the search for safe and effective perioperative anticancer treatments that will serve as a bridge to standard adjuvant therapy.
I 2 We concluded that QoL after BDI was significantly lower compared with healthy controls and patients after uncomplicated LC. Recently, 2 studies from the United States showed different results of QoL after successful functional repair of a BDI. 3, 4 Since we are fascinated by these results, we recently conducted a new follow-up study on 460 patients to evaluate QoL after BDI, including the patients reported in our previous study. 1 During this second evaluation, we noticed a flaw in the syntax used in the first study to calculate the scale scores for the SF-36. In this letter, we briefly summarize the original findings, provide the new data according to the corrected syntax, and discuss the implications. A total of 106 consecutive patients participated in the study. Outcome was evaluated according to type of treatment (endoscopic or surgical) and type of injury. Objective outcome (interventions, hospital admissions, and laboratory data) was evaluated, and risk factors for a worse outcome were calculated. SF-36 scores of BDI patients were compared according to type of treatment and type of injury. SF-36 scores of all BDI patients were compared with those of healthy age-and sex-matched Dutch controls, and of patients who had undergone uncomplicated LC, derived from an ongoing study among patients undergoing elective cholecystectomy. 5 The median follow-up time was 70 months (range, 37-110 months). The objective outcome of endoscopic treatment (n ϭ 69) was excellent (94%). The result of surgical treatment (n ϭ 31) depended on the timing of reconstruction (overall success, 84%; in case of delayed hepaticojejunostomy, 94%). Despite this excellent objective outcome, SF-36 scores of patients with BDI were significantly lower than those of healthy controls and those of patients who underwent uncomplicated LC. Based on univariate and multivariate regression analyses, worse QoL was not dependent on the type of treatment used (endoscopic or surgical) or on the severity of the type of injury. The duration of the treatment was independently prognostic for a worse mental QoL.
When we analyzed the SF-36 findings in the second study, and in particular those for the subgroup of patients originating from the first study, to compare QoL after 5 and 10 years of follow-up, the results did not match those reported in the aforementioned paper. It came to our notice that the syntax used to compute the scales of the SF-36 in the first study included an error, resulting in scale scores that did not range from 0 to 100, but from 0 to 60 or 80, dependent on the scale. No one involved in the study was aware of this error.
The scale scores of the BDI patients in Table 5 and Figure 2 of the original paper are therefore lower than they should have been. The erroneous linear transformation of the raw scores does not affect the comparisons among the BDI patients. However, it does affect the comparison with healthy controls and patients with uncomplicated LC. It should be noted that the reported scale scores of these latter 2 groups are correct, as they were taken from other studies. 5 Reanalyses of the comparison of QoL scores of the BDI patients with those of healthy controls revealed significant differences (P Ͻ 0.05) for 6 of the 8 scales. Insignificant differences were found for physical functioning and bodily pain ( Table 1 ). The correct mean scores of the BDI patients and the originally reported scores of healthy controls and patients with uncomplicated LC are presented in Figure 1 .
Although the differences in QoL scores are in the same direction, the magnitude of these differences is smaller for BDI patients compared with healthy controls, and with patients with uncomplicated LC, respectively.
Of additional interest are 2 studies mentioned above: Moore et al 3 found that, at a mean follow-up of 5 years after BDI, 50 patients had significantly lower scores on the SF-36 in comparison to 74 patients with uncomplicated LC, and to general U.S. population norms, respectively. These BDI patients were treated endoscopically and surgically. However, Sarmiento et al 4 found that, at a mean of 8.4 years of follow-up after surgical repair for BDI (n ϭ 45), SF-36 scores were comparable both to those of a matched control population of patients undergoing uneventful LC and to those of U.S. norms. The results of these studies may differ because of differences in type of treatment and duration of follow-up. QoL research in BDI patients is important. The possible iatrogenic condition is in no other population as evident as in BDI patients. However, given the heterogeneity of the studies to date, the potentially detrimental consequences for patients' QoL need to be further explored. We are currently examining BDI patients' QoL by using a large sample size (n ϭ 460), including patients who had undergone different treatments, assessing patients at different times of follow-up, and using generic and disease-specific QoL measures. We are additionally investigating the extent to which clinical, socio-demographic, and psychosocial factors affect these patients' QoL. This study will help to better characterize BDI patients in terms of clinical and QoL outcomes. More specifically, this study will help to identify those patients who are most vulnerable and in need of special care.
We think that we should communicate this failure in syntax not only to the Editor but also to the surgical community. To prevent possible mistakes in the future, the departments of Clinical Epidemiology and Biostatistics, and Medical Psychology of our hospital have devised an intranet site, including standard form of QoL questionnaires and syntaxes that can be downloaded by those involved in QoL assessment. considerable interest. Their finding that Roux limb length does not significantly affect weight loss at 10 years following Roux-en-Y gastric bypass (RYGB) conflicts with shorter-term weight loss results in previously published prospective randomized comparisons (including their own) of Roux limb length in bariatric surgical patients. 2,3 I was most surprised that the authors chose not to cite or discuss the results of those shorterterm studies in their recent publication. However, in many ways, their findings at 10 years postoperatively are not surprising. It is common knowledge that most bariatric surgical patients regain some portion of their lost weight 2 to 3 years after the nadir of weight loss. The weight regain phenomenon supports the concept that obesity is a chronic, even progressive disease (much like atherosclerosis) that is highly resistant to current methods of medical and surgical treatment. Regain is likely due to the adaptive anatomic and physiologic changes that occur after all bariatric operations. Because the stomach is designed to stretch, stomal dilatation is a universal occurrence following proce-dures that do not incorporate prosthetic stomal reinforcement. Hence, some portion of the so-called "satiety response" is lost following unbanded RYGB. Absorptive capacity of the functional small bowel also increases over time. 4, 5 They also found that superobese patients both lose and regain their weight more rapidly than less severely obese patients, attesting to the "incorrigibility" of this subset of severely obese patients.
In my view, the authors' use of the Reinhold scale for classification of postoperative weight loss results is both simplistic and short-sighted. Although this system likely bears some relationship with improved health status and possibly longevity, it does not in any way account for improvement or resolution of obesity-related comorbidities, which tends to occur in many patients with relatively modest weight loss. For example, a 5 foot 5 inch woman with weight/ BMI of 400 pounds/67 kg/m 2 losing to 220 pounds/37 kg/m 2 would be classified as a "failure," according to Reinhold's classification. I am also curious as to why 70% of the superobese patients in their study had short-limb operations. Moreover, the authors do not specifically mention how many of the 30 superobese patients who had long-limb operations were followed at 5 and 10 years postoperatively.
The authors also make an interesting "apples versus oranges" comparison in Table 5 , which shows a similar failure rate between their series of RYGB gastric bypass and the Quebec group's results with biliopancreatic diversion/duodenal switch (BPD/DS). These results are contradicted by the recent prospective comparison of RYGB versus BPD/DS from the University of Chicago, which showed significantly greater weight loss favoring the duodenal switch 6 months postoperatively. 6 The preponderance of available clinical data shows that adding malabsorption to gastric restriction improves short-term weight loss in bariatric surgical patients. These data include all of the prospective randomized comparisons of purely restrictive operations versus RYGB and the recent comparison of RYGB versus BPD/DS. 6 It seems reasonable and appropriate to give superobese patients a "jump start" in their Annals of Surgery • Volume 246, Number 1, July 2007 Letters to the Editor weight loss provided that the operation performed provides this benefit at no additional risk. Finally, let me take this opportunity to compliment the authors on the fastidious long-term follow-up of bariatric patients achieved at McGill University Health Centre. Their long-term follow-up is superior to that of all but 1 medical center in North America (East Carolina University) and attests to their diligence in pursuit of long-term outcomes. The McGill group has made tremendous contributions to the field of bariatric surgery during the past 3 decades, and I congratulate them for that.
Robert E. Brolin, MD

Reply:
W e welcome the comments and questions of Robert Brolin. It was not that long ago that students of obesity thought that the impressive weight loss after gastric bypass remained stable for at least 14 to 15 years following the operation. 1, 2 We now know there is significant weight gain continuously after the nadir weight at 2 to 3 years. This is especially apparent when all patients are followed for at least 10 years so that weight gained is not masked by the greater losses achieved by patients followed for shorter periods.
Our earlier studies confirmed the work of Brolin et al that long-limb gastric bypass achieved greater weight loss in the superobese after 5 years. 3 This was not seen in the morbidly obese but was especially valuable for patients with a BMI Ն60 kg/m 2 . When these patients were followed for at least 10 years, these advantages of the long limb were no longer significant.
The reason we use the Reinhold scale is to replace the haze of means with the precision of individual results. We also wanted to compare our results with our previous report of the same patient cohort. 3 Not all patients gain weight with time after gastric bypass; and if we are going to improve surgical results, we must determine why. For example, 8 of 63 patients who were superobese got an excellent result (BMI Յ30 kg/m 2 ) after 10 years. We cannot confirm that superobese patients are incorrigible.
Our paper, as we carefully state, is a retrospective study. We changed our operation from short limb to long limb on a certain date. All patients were followed for a mean of 11.4 years. All patients reported in Table 2 , including the superobese patients, were followed for more than 10 years.
We are at a loss to explain the average 55% excess weight loss (EWL) at 5 years reported in the review of all publications to September 2005 by O'Brien et al. 4 Our surgical technique of a small 5-to 10-mL vertically oriented gastric pouch results in 78% EWL at 5 years. We do not think that a vertical gastric pouch necessarily stretches, especially if it is not banded and if it is made very small. The majority of surgeons now create a horizontal pouch, especially those using minimally invasive laparoscopic techniques that are large enough to permit mechanical stapling of the gastrojejunostomy. We think that these 30-mL pouches are already too large and prone to stretching and may account for the 55% EWL at 3 to 5 years reported by other centers. We use a hand-sewn gastrojejunostomy with a very small vertically based gastric pouch in our current laparoscopic approach to bariatric surgery as per our open technique prior to February 2002. Preliminary results at 3 years show 82% EWL.
We agree that adding malabsorption to gastric restriction, as in the biliopancreatic diversion with duodenal switch, is likely to promote significantly greater weight loss in the superobese, but we are not certain of the late results as yet. Our colleagues at the University of Laval in Quebec City are equally experienced with their technique of BPD/DS and their long-term follow-up (up to 15 years) shows equivalent weight loss to Roux-en-Y gastric bypass as performed in our center. Prachand et al 5 short-term results of 54.9% EWL for gastric bypass at 36 months highlight our concern with large 15-to 30-mL gastric pouches and stapled gastrojejunostomies. Their 68.9% EWL at 36 months with duodenal switch is much less than the 82% EWL with gastric bypass in our series. Additionally, our results for superobese patients at 11.4 years of follow-up with BMI ϭ 38.3 kg/m 2 compare favorably to that of Prachand et al of 37.2 for the duodenal switch operation in superobese patients at 3 years. Our patients regained at least 10% to 15% of their EWL after more than 10 years of follow-up. We look forward to the long-term follow-up of Prachand et al to see if their %EWL will follow similar trends.
We agree that we need a better classification of success that reflects degrees of excess weight preoperatively that might make it easier to compare results.
We thank Dr. Brolin for his kind remarks.
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